DEXTERITY DURABILITY GRIP

FIRM TOUCH 6040MD

LOW DERMATITIS POTENTIAL

Powder Free Nitrile Examination Glove

ELITE SAFETY PRODUCTS



LOW DERMA™ Technology in Skin Protection

Patented Technology *

* Patent *www.lowderma.com/patents*

REDEFINING HAND PROTECTION

The 6040MD is a revolutionary, new generation nitrile glove. This glove is the 1st U.S. FDA granted products with low dermatitis potential claim. It does not use sulfur and accelerators in the manu-facturing process. The unique technology reduces risk from delayed Type IV hypersensitivity caused by residual chemicals accelerator such as thiurams, carbamates and thiazoles. Clinical studies performed on 6040MD with Modified Draize-95 Test and on Japanese patients with contact dermatitis concluded that there is no evidence of induced allergic contact dermatitis on human subject. Thus 6040MD glove is the solution for users who aresuffering from Type IV hypersensitivity.

FEATURES & BENEFITS

- **Pure**
  Clean glove with no sulfur and no accelerators added in the formulation
- **Performance**
  Modified Draize-95 tested negative & superior barrier protection against blood-borne pathogen and viruses
- **Protection**
  Prevent Type I Natural Rubber Latex allergy and reduce potential risk of Type IV hypersensitivity. Safe for food handling.

RECOMMENDED APPLICATIONS

Healthcare · Dental · Laboratory · Ind. Safety · Veterinary · Food Handling · Beauty · Law · Agriculture · Household

RESISTANCE OF GLOVES TO PERMEATION BY CHEMICALS AND CHEMOTHERAPY DRUGS

Resistance to Permeation by Chemicals (EN 374:2003 Part 3)	Level
5% Ethidium Bromide	6
37% Formaldehyde	6
50% Glutaraldehyde	6
1.5% Methanol in Water	6
0.1% Phenol	6
40% Sodium Hydroxide	6
10-13% Sodium Hypochlorite	6
50% Sulphuric Acid	6

with measured breakthrough time of minimum 480 minutes for level 6

CHEMOTHERAPY DRUGS AND FENTANYL (ASTM D6978-05 (2013))	
Cisplatin *Cyclophosphamide (Cytoxan) Cytarabine Dacarbazine *Doxorubicin Hydrochloride *Etoposide Fentanyl Citrate *Fluorouracil Ifosfamide Methotrexate Mitomycin C Mitoxantrone *Paclitaxel (Taxol) Vincristine Sulfate	No Breakthrough after 240 minutes
*Thiotepa	90 minutes
*Carmustine	10 minutes

** denotes mandatory chemotherapy drugs*

PRODUCT SPECIFICATIONS & TYPICAL PERFORMANCE (ASTM D6319 & EN 455)

	SPEC	TYPICAL
Thickness (mm)		
Cuff	Min. 0.05	0.06 - 0.07
Palm	Min. 0.06	0.07 - 0.08
Finger	Min. 0.08	0.12 - 0.13
Dimension (mm)		
Length	Min. 240	244 - 246
Physical Properties - Unaged		
Tensile Strength (MPa)	Min. 14	26 - 34
Elongation (%)	Min. 500	540 - 580
Force at Break (N)	Min. 6.0	7.3 - 8.8
Physical Properties - Aged		
Tensile Strength (MPa)	Min. 14	31 - 37
Elongation (%)	Min. 400	560 - 580
Force at Break (N)	Min. 6.0	8.5 - 9.3

** typical product performance not to be taken as actual product specifications*

COLOR CODE



Images are for Illustrative purposes only

PRODUCT TESTAMENT

* Comply to International Standards (ASTM D6319 & EN455)
FDA 510(k) Pre-market Notification

Biological Evaluation

Primary Skin Irritation Test
Dermal Sensitization Assay
Cytotoxicity Test

Additional Test

Viral Penetration (ASTM F1671)
Chemotherapy Drugs (ASTM D6978)
Chemical Residue Modified Draize-95
Japanese Clinical Dermatology

Food Handling

US FDA 21 CFR 177.2600
(EU) No. 10/2011(EN 1186)

MDD Compliance

MDD 93/42/EEC

PPE Compliance

PPE 89/686/EEC, CAT III

PACKAGING INFORMATION

Packing

Box Dimension (inch) : 9.5x4.75x2.75"
100pcs/box, 10box/case

PRODUCT ATTRIBUTES

Powder-Free Chlorinated | Fingertips Textured | Ambidextrous
Low Dermatitis Potential | Standard Cuff | Beaded | AQL 1.5

LATEX NON STERILE CE 0120
EN 374-2 Level 2 EN 374-1

STRETCHING LIMITS • SINCE 1979